Publications in collaboration with researchers from Hospital Universitari de Bellvitge (15)

2024

  1. 2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?

    Contact Dermatitis, Vol. 90, Núm. 5, pp. 507-513

  2. Sensitization to textile dyes in Spain: Epidemiological situation (2019–2022)

    Contact Dermatitis, Vol. 90, Núm. 5, pp. 486-494

  3. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64

  2. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 291-298

  3. Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas

  4. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation

    Contact Dermatitis, Vol. 88, Núm. 3, pp. 212-219

2022

  1. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases*

    British Journal of Dermatology, Vol. 187, Núm. 5, pp. 765-772

2021

  1. Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology

2020

  1. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

    British Journal of Dermatology, Vol. 183, Núm. 1, pp. 71-77

  2. Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study

    Dermatologic Therapy, Vol. 33, Núm. 6

  3. Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 5, pp. 1535-1538

2019

  1. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study

    Journal of Dermatological Treatment, Vol. 30, Núm. 5, pp. 461-465

2018

  1. The First Year of the AEVD Primary Cutaneous Lymphoma Registry

    Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 610-616

2016

  1. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

    Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209